BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22359591)

  • 1. No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease.
    Tian L; Karimi M; Loftin SK; Brown CA; Xia H; Xu J; Mach RH; Perlmutter JS
    PLoS One; 2012; 7(2):e31439. PubMed ID: 22359591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.
    Tian L; Karimi M; Brown CA; Loftin SK; Perlmutter JS
    Brain Res; 2014 Jul; 1571():49-60. PubMed ID: 24845719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
    Jourdain S; Morissette M; Morin N; Di Paolo T
    J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease.
    Al-Sweidi S; Morissette M; Bourque M; Di Paolo T
    Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice.
    Miville-Godbout E; Bourque M; Morissette M; Al-Sweidi S; Smith T; Mochizuki A; Senanayake V; Jayasinghe D; Wang L; Goodenowe D; Di Paolo T
    PLoS One; 2016; 11(3):e0151020. PubMed ID: 26959819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coordinated expression of dopamine transporter and vesicular monoamine transporter in the primate striatum during development.
    Elsworth JD; Redmond DE; Roth RH
    Synapse; 2013 Sep; 67(9):580-5. PubMed ID: 23468413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
    Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
    Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
    Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
    Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
    Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
    J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO
    Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons.
    Hong J; Sha S; Zhou L; Wang C; Yin J; Chen L
    Cell Death Dis; 2015 Jul; 6(7):e1832. PubMed ID: 26203861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment.
    Smith TS; Trimmer PA; Khan SM; Tinklepaugh DL; Bennett JP
    Brain Res; 1997 Aug; 765(2):189-97. PubMed ID: 9313891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
    Suzuki M; Desmond TJ; Albin RL; Frey KA
    Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
    Fujita A; Fujita Y; Pu Y; Chang L; Hashimoto K
    Psychopharmacology (Berl); 2020 Jan; 237(1):83-92. PubMed ID: 31418048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.
    Miller GW; Erickson JD; Perez JT; Penland SN; Mash DC; Rye DB; Levey AI
    Exp Neurol; 1999 Mar; 156(1):138-48. PubMed ID: 10192785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.